Physician profile
Augustus Valmond
NPI 1225055676
$14,879.36
in general payments reported to CMS, 2019-2025
32 companies · $3,194 in 2025
The $3,194 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,317 · 2020: $3,571 · 2021: $676 · 2022: $1,028 · 2023: $647 · 2024: $1,446 · 2025: $3,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,287.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,526.53 | 2019-2020 | |
| Gilead Sciences, INC. | $1,612.65 | 2019-2025 | Yeztugo |
| Viiv Healthcare Company | $1,513.95 | 2019-2025 | Apretude, Dovato |
| Amgen INC. | $1,499.17 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,244.72 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Novo Nordisk INC | $1,226.23 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,056.44 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $898.57 | 2021-2025 | Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $472.59 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $452.96 | 2019-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.31 | 2019-2025 | Jardiance |
| Medtronic USA, INC. | $363.82 | 2019 | |
| Pfizer INC. | $315.68 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.39 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $146.46 | 2025 | Caplyta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $136.38 | 2023-2024 | Quviviq |
| Astellas Pharma US INC | $128.57 | 2019 | |
| Acorda Therapeutics, INC | $122.06 | 2019 | |
| Radius Health, INC. | $117.81 | 2019 | |
| Napo Pharmaceuticals INC | $58.76 | 2019 | |
| Lundbeck LLC | $54.98 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $50.30 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $47.48 | 2024 | |
| Braintree Laboratories, INC. | $37.30 | 2019 | |
| Merz North America, INC. | $36.00 | 2025 | |
| Genentech USA, INC. | $30.73 | 2019 | |
| Ardelyx, INC. | $29.55 | 2025 | Ibsrela |
| Abbott Laboratories | $27.57 | 2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $24.73 | 2019 | |
| Nestle Healthcare Nutrition INC. | $21.39 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $19.95 | 2025 | Neffy |
| Vifor Pharma, INC. | $17.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustus Valmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.